MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Neoleukin Therapeutics Balance Sheet 2011-2025 | NLTX
Annual Balance Sheet Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-146 M | -81.3 M | -141 M | -193 M | -142 M | -76.9 M | -52 M | -32.3 M | -39.5 M | -14.9 M | -8.72 M | -2 M | - |
Long Term Debt |
65 K | 66 K | 67 K | 11.3 K | - | - | - | - | - | - | 2.04 M | - | - |
Long Term Debt Current |
2.56 M | 678 K | 1.17 M | 659 K | 556 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 11.4 M | 593 K | 319 K | 486 K | 197 K | 131 K | 72.3 K | 2.27 M | 53.1 M | - |
Total Current Liabilities |
23 M | 6.65 M | 8.64 M | 7.89 M | 4.74 M | 4.63 M | 11 M | 9.52 M | 4.79 M | 5.2 M | - | - | - |
Total Liabilities |
36.5 M | 10.6 M | 20.4 M | 19.3 M | 5.34 M | 4.95 M | 11.4 M | 9.72 M | 4.92 M | 5.28 M | 4.89 M | 53.4 M | - |
Retained Earnings |
-187 M | -151 M | -393 M | -333 M | -300 M | -230 M | -199 M | -148 M | -111 M | -89.4 M | -63.6 M | -51.6 M | - |
Total Assets |
223 M | 109 M | 163 M | 211 M | 147 M | 77.6 M | 110 M | 154 M | 113 M | 41.4 M | 15.6 M | 2.34 M | - |
Cash and Cash Equivalents |
148 M | 82 M | 142 M | 193 M | 143 M | 76.9 M | 52 M | 32.3 M | 39.5 M | 14.9 M | 11 M | 2 M | - |
Book Value |
186 M | 98.6 M | 143 M | 191 M | 142 M | 72.7 M | 98.9 M | 145 M | 108 M | 36.1 M | 10.8 M | -51.1 M | - |
Total Shareholders Equity |
186 M | -146 M | 143 M | 191 M | 142 M | 72.7 M | 98.9 M | 145 M | 108 M | 36.1 M | -65.7 M | -51.1 M | - |
All numbers in USD currency
Quarterly Balance Sheet Neoleukin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
7 K | 9 K | 17 K | 26 K | 39 K | 53 K | - | 65 K | 5 K | 6 K | 7 K | 233 K | 9 K | 10 K | 66 K | 67 K | 68 K | 68 K | 122 K | 108 K | 108 K | 108 K | 108 K | 146 K | 146 K | 146 K | 146 K | 6 K | 6 K | 6 K | 6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
22.3 M | 24.1 M | 23.5 M | 25.4 M | 26.7 M | 24.8 M | - | 36.5 M | 14.4 M | 14.4 M | 17.1 M | 21.6 M | 20.9 M | 20.3 M | 19 M | 20.4 M | 21.1 M | 20 M | 21.1 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 5.34 M | 5.34 M | 5.34 M | 5.34 M | 4.95 M | 4.95 M | 4.95 M | 4.95 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 9.72 M | 9.72 M | 9.72 M | 9.72 M | 4.92 M | 4.92 M | 4.92 M | 4.92 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 7.48 M | 7.48 M | 7.48 M | 7.48 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-328 M | -307 M | -285 M | -262 M | -243 M | -223 M | - | -187 M | -472 M | -467 M | -465 M | -451 M | -438 M | -425 M | -409 M | -393 M | -378 M | -363 M | -348 M | -333 M | -333 M | -333 M | -333 M | -300 M | -300 M | -300 M | -300 M | -230 M | -230 M | -230 M | -230 M | -199 M | -199 M | -199 M | -199 M | -148 M | -148 M | -148 M | -148 M | -111 M | -111 M | -111 M | -111 M | -89.4 M | -89.4 M | -89.4 M | -89.4 M | -65.7 M | -65.7 M | -65.7 M | - | - | - | - | - | - | - | - | - |
Total Assets |
288 M | 297 M | 315 M | 336 M | 164 M | 180 M | - | 223 M | 89.6 M | 94 M | 98.5 M | 116 M | 127 M | 137 M | 149 M | 163 M | 176 M | 187 M | 200 M | 211 M | 211 M | 211 M | 211 M | 147 M | 147 M | 147 M | 147 M | 77.6 M | 77.6 M | 77.6 M | 77.6 M | 110 M | 110 M | 110 M | 110 M | 154 M | 154 M | 154 M | 154 M | 113 M | 113 M | 113 M | 113 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
71 M | 58.8 M | 70.8 M | 137 M | 67 M | 111 M | 150 M | 148 M | 45.6 M | 59 M | 35.5 M | 37.9 M | 41.2 M | 78.4 M | 129 M | 142 M | 156 M | 165 M | 178 M | 193 M | 193 M | 193 M | 193 M | 143 M | 143 M | 143 M | 143 M | 76.9 M | 76.9 M | 76.9 M | 76.9 M | 52 M | 52 M | 52 M | 52 M | 32.3 M | 32.3 M | 32.3 M | 32.3 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 11 M | 11 M | 11 M | 11 M | 2 M | - | - | - | 9.24 M | - | - | - |
Book Value |
266 M | 273 M | 292 M | 310 M | 137 M | 155 M | - | 186 M | 75.2 M | 79.6 M | 81.4 M | 94.3 M | 106 M | 117 M | 130 M | 143 M | 155 M | 167 M | 179 M | 191 M | 191 M | 191 M | 191 M | 142 M | 142 M | 142 M | 142 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 98.9 M | 98.9 M | 98.9 M | 98.9 M | 145 M | 145 M | 145 M | 145 M | 108 M | 108 M | 108 M | 108 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 8.17 M | 8.17 M | 8.17 M | 8.17 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
266 M | 273 M | 292 M | 310 M | 137 M | 155 M | 171 M | 186 M | -183 M | -169 M | 81.4 M | 94.3 M | 106 M | 117 M | 130 M | 143 M | 155 M | 167 M | 179 M | 191 M | 191 M | 191 M | 191 M | 142 M | 142 M | 142 M | 142 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 98.9 M | 98.9 M | 98.9 M | 98.9 M | 145 M | 145 M | 145 M | 145 M | 108 M | 108 M | 108 M | 108 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | -65.7 M | -65.7 M | -65.7 M | -65.7 M | -51.1 M | - | - | - | -39.3 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Neoleukin Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Drug manufacturers
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
$ 1.69 | -3.16 % | $ 182 M |  Canada |
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
$ 0.73 | -3.54 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
$ 3.05 | -6.72 % | $ 1.63 B | Canada |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
$ 5.17 | -4.22 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
$ 4.78 | -0.83 % | $ 629 M | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
$ 12.03 | 5.34 % | $ 616 M | USA |
 |
Pacira BioSciences
PCRX
|
$ 26.7 | 1.56 % | $ 1.23 B | USA |
 |
Evoke Pharma
EVOK
|
$ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
$ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Rockwell Medical
RMTI
|
$ 0.87 | -5.71 % | $ 20.3 M | USA |
 |
Evolus
EOLS
|
$ 7.18 | 1.92 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
$ 45.82 | -2.64 % | $ 1.49 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
$ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
China Pharma Holdings
CPHI
|
$ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
$ 6.88 | -0.65 % | $ 2.51 B | Canada |
 |
Veru
VERU
|
$ 2.44 | 0.83 % | $ 329 M | USA |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
$ 1.8 | -6.51 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
$ 3.05 | 20.47 % | $ 42.9 M | USA |
 |
cbdMD
YCBD
|
$ 1.39 | 13.52 % | $ 5.99 M | USA |
 |
Solid Biosciences
SLDB
|
$ 5.81 | -1.11 % | $ 237 M | USA |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
$ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
$ 12.86 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
$ 0.12 | 0.17 % | $ 1.9 M | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
$ 1.96 | -11.31 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
$ 0.64 | -1.25 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
$ 11.6 | -4.56 % | $ 7.17 B | Canada |
 |
TherapeuticsMD
TXMD
|
$ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
$ 11.66 | 0.09 % | $ 14.1 B | USA |